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The receptor for the cardiac hormone atrial natriuretic peptide (ANP), natriuretic peptide receptor A (NPR-A), has
been reported to be expressed in lung cancer, prostate cancer and ovarian cancer. NPR-A expression and signaling
is important for tumor growth; its deficiency protects C57BL/6 mice from lung, skin and ovarian cancers. This suggests
that NPR-A is a new marker and a new target for cancer therapy. Recently, NPR-A has been demonstrated to be
expressed in pre-implantation embryos and in embryonic stem cells, which has a novel role in the maintenance of
self-renewal and pluripotency of embryonic stem cells. A nanoparticle-formulated interfering RNA for NPR-A attenuated
B16 melanoma tumors in mice. Ectopic expression of a plasmid encoding NP73-102, the NH2-terminal peptide of the
ANP prohormone which downregulates NPR-A expression, also suppressed lung metastasis of A549 cells in nude mice
and tumorigenesis of Line 1 cells in immunocompetent BALB/c mice. These results suggest that NPR-A is involved in
tumorigenesis and a new target for cancer therapy. This review focuses on structure, abnormal functions and carcinogenic
mechanisms of NPR-A to investigate its role in tumorigenesis.
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Introduction
Natriuretic peptide receptor A (NPR-A) is the receptor
for atrial natriuretic peptide (ANP) and brain natriuretic
peptide (BNP). ANP and BNP, members of the natriuretic
peptide family, have been extensively studied for their
functions in regulating blood pressure. Both ANP and
BNP signal through NPR-A by increasing cGMP and acti-
vating cGMP-dependent protein kinase G (PKG). Acti-
vated PKG in turn upregulates expression of genes
encoding ion transporters and transcription factors, which
together affect cell growth, apoptosis, proliferation, and
inflammation [1-3]. The human NPR-A gene is located on
chromosome 1q21-22 and consists of 22 exons and 21
introns within 16 kb. NPR-A and/or its mRNA is
expressed in kidney, lung, adipose, adrenal, brain, heart,
testis, and vascular smooth muscle tissue [4-7]. Recent
research suggests, however, that NPR-A expression and
signaling is important for tumor growth. NPR-A deficiency
protected C57BL/6 mice from lung, skin, and ovarian can-
cers. Furthermore, a nanoparticle-formulated interfering* Correspondence: wangjshxjtu@gmail.com
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unless otherwise stated.RNA for NPR-A attenuated B16 melanoma tumors in
mice. Ectopic expression of a plasmid encoding NP73-102,
the NH2-terminal peptide of the ANP prohormone which
downregulates NPR-A expression, also suppressed lung
metastasis of A549 cells in nude mice and tumorigenesis of
Line 1 cells in immunocompetent BALB/c mice. These re-
sults suggest that NPR-A is involved in tumorigenesis and
a new target for cancer therapy [8,9]. This review focuses
on structure, abnormal functions and carcinogenic mecha-
nisms of NPR-A to investigate its role in tumorigenesis.The structure of natriuretic peptide receptor A
The human NPR-A gene is approximately 16 kb, contains
22 exons and 21 introns, and is located on chromosome
1q21–22 that encodes a 1,061-amino acid peptide [5,10].
The NPR-A gene product is abundantly expressed in the
vascular system, kidneys, and adrenal glands [11]. NPR-A
has been cloned and sequenced from rat brain [12,13],
human placenta [14], and mouse testis [15]. The general
topological structure of NPR-A is consistent with that in
the GC receptor family, containing at least four distinct
regions: an extracellular ligand-binding domain (ECD), a
single transmembrane spanning region, an intracellular
protein kinase-like homology domain (protein-KHD), andLtd. This is an Open Access article distributed under the terms of the Creative
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receptor requires ANP binding to the ECD and phosphor-
ylation of up to six residues within the KHD [17]. After
ANP binding to NPR-A, activation of the intrinsic GC
leads to an intracellular increase in cGMP which in turn
can activate different downstream effectors involved in
cell growth, apoptosis, proliferation and inflammation,
through the activation of cGMP-dependent PKG [3].
The ECD contains a highly conserved chloride-binding
site near the ECD dimerization interface [18,19]. The ECD
also contains in its juxtamembrane region a highly con-
served structural motif, referred to as the receptor-GC sig-
naling motif [20]. Single-residue mutations in this motif
either render the receptor unresponsive to ligand binding
or cause constitutive activation of GC activity [21], sug-
gesting that this conserved structure plays a critical role in
transmembrane signal transduction. The ECD contains
three disulfide bonds, Cys60–Cys86, Cys164–Cys213 and
Cys423–Cys432, in a 1–2, 3–4 and 5–6 linkage pattern
[22]. Of these, the disulfide bond Cys60–Cys86 occurs in
the chloride-binding site, and the disulfide bond Cys423–
Cys432 occurs in the juxtamembrane receptor-GC motif.
Both disulfide bonds are conserved among the A-type and
B-type natriuretic peptide receptors. The ECD also con-
tains five N-linked oligosaccharides [23]. Correct glycosyl-
ation is essential for expression of functional NPR-A:
deletion of any one of the five glycosylation sites by muta-
genesis reduces or abolishes NPR-A expression [24]. On
the other hand, deglycosylation of the native or expressed
ECD with endoglycosidase F2 or H has no effect on ANP
binding [25]. Together, these findings suggest that glyco-
sylation is essential for folding or transport of the nascent
receptor polypeptide to the cell membrane, but that, once
the active receptor is formed, the glycosyl moieties are not
involved in ANP binding. This notion is consistent with
the crystal structure of the ANP–ECD complex [18],
which shows that glycosyl moieties or the glycosylation
sites are located away from the ANP-binding site.
The KHD contains an approximately 280-amino acid
region that immediately follows the transmembrane span-
ning domain of the receptor. The KHD of NPR-A is more
closely related to protein tyrosine kinases than protein
serine/threonine kinases. In fact, it is largely similar to the
protein kinase domain of the platelet-derived growth
factor receptor with approximately 31% amino acid
sequence identity between the comparable regions of the
kinase domains [5,12,15]. It has been demonstrated that
the KHD of NPR-A serves an important mediatory role in
transducing the ligand-induced signals to activate the GC
catalytic domain of the receptor [16,26,27]. It has been
suggested that an intervening step involving the KHD is
necessary for the cyclase catalytic activation process
[24,28,29]. Several studies have suggested that ATP serves
as an intracellular allosteric regulator of the KHD for theactivation of NPR-A [27,30-33]. ATP is thought to func-
tion by interacting with the KHD because this region
contains a glycine-rich nucleotide-binding motif and has
been postulated to provide an ATP-regulatory module for
ANP signaling [27,34]. It has been also suggested that
binding of ANP to NPR-A activates ATP binding to the
KHD in the intracellular cytoplasmic space, which, in
turn, activates the GC catalytic domain of the receptor
[27,28,35]. Indeed, previous studies as well as recent data
have indicated that the KHD seems to be important for
ANP-dependent activation of NPR-A [36,37]. However,
the exact mechanisms of activation and relay of signals
from the KHD to the GC catalytic active site of the receptor
remain to be established.
The GC catalytic domain of NPR-A contains an approxi-
mately 250-amino acid region that constitutes the catalytic
active site of the receptor [38-40]. The transmembrane GC
receptors contain a single cyclase catalytic active site per
polypeptide molecule; however, based on the structure
modeling data [41] two polypeptide chains seem to be re-
quired to activate NPR-A, and the receptor functions as a
homodimer [42-44]. Initially, the dimerization region of
the receptor was believed to be located between the KHD
and GC domain that has been suggested to form an
amphipathic alpha helix structure [45]. It has been
reported that the crystal packing of the extracellular
ligand-binding domain of NPR-A contains two possible
dimer pairs, the head-to-head and tail-to-tail dimer pairs
associated through the membrane-distal and membrane-
proximal subdomains, respectively [46]. The tail-to-tail
dimer of NPR-A has been proposed previously [41]. The
crystal structure of NPRC has also suggested that NPRC is
dimerized in head-to-head configuration bound with ligand
CNP [47]. It has been previously proposed that the
head-to-head dimer may represent the latent inactive
state and the tail-to-tail dimer could represent the
hormone-activated state [48]. It has also been indicated
that ligand-dependent activation of NPR-A stabilizes a
membrane-distal dimer interface of this receptor protein
suggesting that ANP binding stabilizes the NPR-A dimer
with more stringent spacing at the dimer interface [49].
However, more recently, the results of site-directed muta-
genesis and chemical modification studies suggested that
head-to-head dimer structure reflects the physiological
dimer structure of NPR-A [46].
Natriuretic peptide receptor A and cancer
Almost all studies of NPR-A expression have focused on
heart, kidney or other tissues. In 1993, Ohsaki and col-
leagues reported that functional ANP A receptors (NPR-A)
are expressed in human small-cell lung cancer cell lines
and Hela cells for the first time [50]. NPR-A mRNA was
identified by Southern blot analyses of PCR products and
RNase protection assays using poly (A) (+)-selected RNA.
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proliferation of various cancer cells and tumor growth, and
NPR-A is expressed in various cancer cells [51], but he did
not investigate the direct role of NPR-A in tumorigenesis.
Recently the direct role of NPR-A signaling in tumorigen-
esis has been clarified by animal model, interfering RNA,
Western blot and immunohistochemistry [8,9].
Natriuretic peptide receptor A and lung cancer
In 1993, NPR-A mRNA was identified by Southern blot
analyses of PCR products and RNase protection assays
using poly (A) (+)-selected RNA, and it was first
reported expressed in human small-cell lung cancer cell
lines [50]. Western blots results also show that NPR-A is
present in human small-cell lung cancer cells [52]. Kong
and colleagues [8] also found that NPR-A is expressed at
a higher level in lung carcinoma (A549 and LLC1). They
also clarified the direct role of NPR-A in lung cancer [8].
It has been shown NPR-A deficiency decreases lung
inflammation. The data from animal models that com-
pared the lungs of mice deficient in NPR-A (NPR-A−/−)
with those of wild-type mice after immunization with in-
traperitoneal ovalbumin and subsequent challenge with
intranasal ovalbumin showed that C57BL/6 wild-type
mice had substantially higher inflammation, blocked air-
ways, and goblet cell metaplasia than did NPR-A−/−mice.
Bronchoalveolar lavage fluid from NPR-A−/−mice had
significantly reduced levels of the inflammatory cyto-
kines IL-4, IL-5, and IL-6 relative to those in wild-type
mice. Using the Lewis lung carcinoma model, compared
to C57BL/6 wild-type mice, the tumor in NPR-A−/−mice
gradually shrank. This indicates that NPR-A deficiency
significantly protects mice from lung tumorigenesis and
lung tumor progression. NP73-102 nanoparticles were
investigated in the suppression of lung cancer tumori-
genesis [8]. Using a soft agar assay, A549 cells were
transfected with pVAX1, pANP, or pNP73-102, and
in vitro results from the soft agar assay indicated that
cells transfected with pNP73-102 exhibited significantly
decreased colony formation compared to that of non-
transfected cells or cells transfected with pVAX1. Using
a nude mouse model, mice were given 5 × 106 A549 cells
intravenously and weekly instillations of PBS (control) or
nanoparticles carrying pNP73-102 or pVAX1. Three
weeks later, mice were sacrificed and lung sections were
stained with hematoxylin and eosin and examined for
lung nodules. Control animals receiving only PBS
showed nodules and tumors, whereas the NP73-102-
treated group had no tumors. In the BALB/c mice tumor
model, those treated with pNP73-102 nanoparticles
injected weekly showed significantly reduced tumor bur-
den compared to those treated with PBS or pVAX1 con-
trol vector [8]. TUNEL assay, Western blot of the
cleavage of caspase 3 substrates, and PARP show thatNP73-102 induces apoptosis of A549 adenocarcinoma.
Microarray analysis of gene expression of A549 cells
after transfection with pNP73-102 show that pNP73-102
significantly altered the expression of a number of genes.
The upregulated genes were predominantly from the
family of interferon-regulated genes or related signal
transduction pathways, and the downregulated genes
included some involved in inflammation. This indicates
that NP73-102 has anti-inflammatory properties.
To investigate the signal pathway in tumor suppression
in NPR-A deficient mice, whole proteins were extracted
from lungs of wild-type and NPR-A−/−mice and then
probed using primary antibodies against p50, p65,
phospho-p50, and phospho-p65. No significant difference
in NF-κB expression in the lungs was abserved between
wild-type and NPR-A−/−mice. However, the level of the
activated form of NF-κB, phospho-NF-κB (both phospho-
p65 and phospho-p50) was decreased in NPR-A−/−mice.
These results indicate that the role of NPR-A in lung
inflammation may involve NF-κB activation. Immunohis-
tochemistry analysis results from the expression of pRb in
the lungs of wild-type C57BL/6 and NPR-A−/−mice
revealed that NPR-A deficiency induced overexpression of
pRb. Western blot results show that the expression of
vascular endothelial growth factor was decreased in the
lungs of NPR-A-deficient mice. Superarray analysis indi-
cates that the expression of hexokinase 2, glycogen synthase
1, and matrix metallopeptidase 10 were downregulated in
the lungs of NPR-A−/−mice, while the expression of cellular
retinol binding protein 1 was upregulated in the lungs of
NPR-A−/−mice.
Natriuretic peptide receptor A and skin cancer
Kong and colleagues found that NPR-A is expressed at a
higher level in melanoma [8]. siNPR-A nanoparticles
were investigated in the injected melanoma cells wild-
type mice model; the mice were treated twice a week
with a cream containing either synthetic siNPR-A,
psiNPR-A, or Scr, respectively. A significant reduction in
tumor burden was seen in mice treated with siNPR-A
(either with synthetic or psiNPR-A) but not those given
Scr after 4 weeks [8]. This result indicates that siNPR-A
could be used to treat melanomas. Flow cytometry assay
results showed that overexpressing pNP73-102 in B16
melanoma could significantly induce apoptosis but not
that of normal NIH3T3 cells [8]. TUNEL assay also
showed a similar result.
Natriuretic peptide receptor A and ovarian cancer
Kong and colleagues found that NPR-A is expressed at a
higher level in ovarian cancer (SKOV3 and ID8) [8].
Using an animal model, wild-type and NPR-A-deficient
C57BL/6 mice were injected with ovarian cancer cells
and monitored weekly for tumor growth; by week 8, all
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but no tumors were observed in NPR-A-deficient mice
[8]. This indicates NPR-A deficiency could inhibit the
growth of ovarian cancer cells.
Natriuretic peptide receptor A and prostate cancer
In 2005 Western blots revealed that for the first time
NPR-A was present in prostate cancer cells [53]. Kong and
colleagues found that NPR-A is expressed at a higher level
in prostate cancer cells (DU145) [8]. Using Western blot
and reverse transcriptase PCR, Wang and colleagues [9]
demonstrated that NPR-A is abundantly expressed in
tumorigenic mouse and human prostate cells, but not in
non-tumorigenic prostate epithelial cells. Immuno-
histochemistry of tissue microarray showed NPR-A expres-
sion is positively correlated with clinical staging. siNPR-A
or iNPR-A could induce apoptosis in Pca cells by the down-
regulation of NPR-A. This effect was linked to NPR-A-
induced expression of macrophage migration inhibitory fac-
tor (MIF), and it could be significantly reduced by siNPR-
A. Animal models show prostate tumor cells implanted
into mice deficient in NPR-A failed to grow, and iNPR-A
treatment could reduce the tumor burden and MIF expres-
sion in TRAMP-C1 xenografts. It was shown that NPR-A
expression is correlated with MIF expression during
PCa progression by the TRAMP spontaneous PCa model.
Natriuretic peptide receptor A and gastric cancer
Our research mainly focuses on NPR-A and gastric cancer.
NPR-A expression was examined by Western blot, im-
munofluorescence and immunohistochemistry. NPR-A
was downregulated by transfection of NPR-A shRNA. We
demonstrated that NPR-A is abundantly expressed in hu-
man gastric cancer AGS cells, but not in non-tumorigenic
epithelial cells. NPR-A expression showed positive corre-
lation with clinical staging and prognosis in gastric cancer
patients. Downregulation of NPR-A by siNPR-A induced
apoptosis in AGS cells. The mechanism of siNPR-A-
induced anti-AGS effects was linked to NPR-A-induced
expression of KCNQ1, a K + channel overexpressed in
AGS and significantly reduced by NPR-A shRNA.
Natriuretic peptide receptor A and other cancers
NPR-A was also present in pancreatic adenocarcinoma
cells [54], breast adenocarcinoma cells [55], colon adeno-
carcinoma cells [56], renal carcinoma cells [57], glioblas-
toma cells [58], and medullary thyroid carcinoma cells
[59]. Vesely’s group studied the effect of four peptides
(long-acting natriuretic peptide, vessel dilator, kaliuretic
peptide and atrial natriuretic peptide) on the cancer cells;
they concluded that the mechanism of decrease in the
number of cancer cells was via inhibition of DNA synthe-
sis, mediated in part by cyclic GMP; they did not, however,
investigate the role of NPR-A in cancer.Carcinogenic mechanism of natriuretic peptide receptor A
Athough Vesely’s group only focused on the effect of
natriuretic peptides (including ANP) on the proliferation
of various cancer cells and tumor growth and they did
not investigate the role of NPR-A in cancer, they showed
that these peptides decrease expression of NPR-A [60].
The role of NPR-A in cancer has been clarified by Kong
and colleagues using animal models and siRNA [8].
NPR-A-deficient mice showed significantly reduced
antigen-induced pulmonary inflammation. NPR-A defi-
ciency could protect C57BL/6 mice from lung, skin, and
ovarian cancers. A nanoparticle formulated interfering
RNA for NPR-A attenuated B16 melanoma tumors in
mice. Ectopic expression of a plasmid encoding NP73-102
could suppress lung metastasis of A549 cells in nude mice
and tumorigenesis of Line 1 cells in immunocompetent
BALB/c mice by the downregulation of NPR-A expression.
Western blot and immunohistochemistry staining indi-
cated that NF-κB was inactivated while retinoblastoma was
upregulated in the lungs of NPR-A-deficient mice. The ex-
pression of vascular endothelial growth factor was also
downregulated in the lungs of NPR-A-deficient mice com-
pared with that in wild-type mice.
Recently it has been demonstrated that NPR-A is
expressed in pre-implantation embryos and in embryonic
stem cells. Knockdown of NPR-A by RNAi resulted in
phenotypic changes, indicative of differentiation, down-
regulation of pluripotency factors and upregulation of
differentiation genes. NPR-A knockdown also resulted in
a marked downregulation of phosphorylated Akt [61].
These result from pre-implantation embryos and embry-
onic stem cells may give us some clues in the study of
NPR-A in cancer.Conclusion
Although NPR-A has been reported to be expressed in
cancer cells for 30 years [50], it was not until 2008 that
the role of NPR-A in cancer was studied [8]. Until now,
only two papers have clarified the role of NPR-A in can-
cer [8,9]. Our research mainly focuses on the NPR-A
and gastric cancer. We demonstrated that NPR-A is
abundantly expressed on human gastric cancer AGS
cells, but not in non-tumorigenic epithelial cells. NPR-A
expression showed positive correlation with clinical
staging and prognosis in gastric cancer patients. Down-
regulation of NPR-A by siNPR-A induced apoptosis in
AGS cells. The mechanism of siNPR-A-induced anti-
AGS effects was linked to NPR-A-induced expression of
KCNQ1, a K + channel overexpressed in AGS and
significantly reduced by NPR-A shRNA. More research
needs to focus on the role of NPR-A in cancer, which
could clarify the carcinogenic mechanisms of NPR-A
more clearly.
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that NPR-A is a new target for cancer therapy. More
research needs to focus on NPR-A to improve the
efficiency of cancer therapy.
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